
    
      This will be a prospective, open-label, single-arm, historically controlled, multicenter
      phase 3 study measuring the safety, efficacy and pharmacokinetics and tolerability of GC5107
      in subjects with Primary Humoral Immunodeficiency disease (PHID).

      Subjects will receive intravenous infusions of the investigational product at the same dose
      and interval as used for their previous Immunoglobulin intravenous (IGIV) maintenance
      therapy. GC5107 will be administered every 21 or 28 days for a period of 12 months.
    
  